Tumor microenvironment and the response to anticancer therapy

Cancer Biology and Therapy

Volumn 1, Issue 5, 2002, Pages 453-458

  Brown, J Martin ^a  

^a NONE

Author keywords

Acute hypoxia; Chronic hypoxia; Clostridia; Gene therapy; HIF 1; Tirapazamine; Tumor hypoxia

Indexed keywords

ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RADIOSENSITIZING AGENT; TIRAPAZAMINE; TRANSCRIPTION FACTOR; TRIAZINE DERIVATIVE;

ANIMAL; BIOLOGICAL MODEL; CELL HYPOXIA; DRUG EFFECT; HUMAN; METABOLISM; NECROSIS; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MODELS, BIOLOGICAL; NECROSIS; NEOPLASMS; RADIATION-SENSITIZING AGENTS; TRANSCRIPTION FACTORS; TRIAZINES;

EID: 0042031680     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.1.5.157     Document Type: Review

References (69)

1. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Brit J Cancer 1955; 9:539-49.
2. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Brit J Radiol 1953; 26:638-48.
3. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93:266-76. (Pubitemid 32219813)
4. Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979; 52:650-6. (Pubitemid 9239867)
5. Chaplin DJ, Durand RE, Olive PL. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 1986; 12:1279-82. (Pubitemid 16030598)
6. Chaplin DJ, Olive PL, Durand RE. Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res 1987; 47:597-601. (Pubitemid 17009632)
7. Trotter MJ, Chaplin DJ, Olive PL. Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br J Cancer 1989; 59:706-9. (Pubitemid 19148529)
8. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 1996; 56:5522-8. (Pubitemid 27011389)
9. Hill SA, Pigott KH, Saunders MI, Powell ME, Arnold S, Obeid A, et al. Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. British Journal of Cancer 1996; 74 Suppl 27:S260-3.
10. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41:31-40.
11. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999; 53:113-7.
12. Rofstad EK, Sundfor K, Lyng H, Trope CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000; 83:354-9. (Pubitemid 30453576)
13. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999; 59:5863-70. (Pubitemid 30004940)
14. Durand RE. The influence of microenvironmental factors during cancer therapy. In vivo 1994; 8:691-702.
15. Durand RE, Raleigh JA. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res 1998; 58:3547-50. (Pubitemid 28376548)
16. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996; 56:5754-7. (Pubitemid 26422184)
17. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379:88-91. (Pubitemid 26008141)
18. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000; 76:589-605. (Pubitemid 30345160)
19. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359:843-5.
20. Fang J, Yan L, Shing Y, Moses MA. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res 2001; 61:5731-5. (Pubitemid 32769087)
21. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 2002; 41:79-83. (Pubitemid 34223708)
22. Brahimi-Horn C, Berra E, Pouyssegur J. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol 2001; 11:S32-6.
23. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468-72. (Pubitemid 32335942)
24. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292:464-8. (Pubitemid 32335941)
25. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294:1337-40. (Pubitemid 33063099)
26. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60:4693-6.
27. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61:2911-6. (Pubitemid 32691934)
28. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 2002; 62:2493-7. (Pubitemid 34462724)
29. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001; 61:7992-8. (Pubitemid 33049392)
30. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001; 7:3399-403. (Pubitemid 33069972)
31. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000; 6:157-62. (Pubitemid 30171366)
32. Brown JM, Koong A. Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J Natl Cancer Inst 1991; 83:178-85.
33. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986; 12:1239-42. (Pubitemid 16055893)
34. Denny WA, Wilson WR. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Exp Opin Invest Drugs 2000; 9:2889-901.
35. Wouters BG, Delahoussaye YM, Evans JW, Birrell GW, Dorie MJ, Wang J, et al. Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res 2001; 61:145-52. (Pubitemid 32095712)
36. Peters KB, Brown JM. Tirapazamine: A hypoxia-activated topoisomerase II poison. Cancer Research 2002; 62:5248-53. (Pubitemid 35024598)
37. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990; 50:7745-9.
38. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993; 53:4633-6. (Pubitemid 23304391)
39. Lee D-J, Trotti A, Spencer S, Rostock R, Fisher C, von Roemeling R, et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int J Radiat Oncol Biol Phys 1998; 42:811-5. (Pubitemid 28559423)
40. Kovacs MS, Hocking DJ, Evans JW, Siim BG, Wouters BG, Brown JM. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer 1999; 80:1245-51. (Pubitemid 29264086)
41. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group [In Process Citation]. J Clin Oncol 2000; 18:1351-9. (Pubitemid 30159856)
42. Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, et al. Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer. J Clin Oncol 2001; 19:535-42. (Pubitemid 32112868)
43. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 2000; 83:1589-93. (Pubitemid 32001698)
44. Patterson LH, McKeown SR, Ruparelia K, Double JA, Bibby MC, Cole S, et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 2000; 82:1984-90. (Pubitemid 30326460)
45. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001; 187:22-36. (Pubitemid 32195242)
46. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5- fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995; 55:4808-12.
47. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 2000; 7:493-8. (Pubitemid 30156563)
48. Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 2002; 4:40-8. (Pubitemid 34075889)
49. Patterson AV, Williams KJ, Cowen RL, Jaffar M, Telfer BA, Saunders M, et al. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther 2002; 9:946-54.
50. Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M, et al. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002; 196:204-12. (Pubitemid 34110902)
51. Malmgren RA, Flanigan CC. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 1955; 15:473-8.
52. Mose JR, Mose G. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res 1964; 24:212-16.
53. Thiele EH, Arison RN, Boxer GE. Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res 1964; 24.
54. Engelbart K, Gericke D. Oncolysis by clostridia V. Transplanted tumors of the hamster. Cancer Res 1964; 24:239-43.
55. Carey RW, Holland JF, Whang HY, Neter E, Bryant B. Clostridial oncolysis in man. Europ J Cancer 1967; 3:37-46.
56. Heppner F, Mose JR. The liquefaction (oncolysis) of malignant gliomas by a non pathogenic clostridium. Acta Neuro 1978; 12:123-5. (Pubitemid 8377876)
57. Heppner F, Mose J, Ascher PW, Walter G. Oncolysis of malignant gliomas of the brain. 13th Int Cong Chemother 1983; 226:38-45.
58. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997; 57:4537-44. (Pubitemid 27441058)
59. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002; 20:142-52. (Pubitemid 34032605)
60. Lemmon ML, Van Zijl P, Fox ME, Mauchline ML, Giaccia AJ, Minton NP, et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther 1997; 4:791-6. (Pubitemid 27380161)
61. Liu SC, Minton NP, A.J. G, J.M. B. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Therapy 2002; 9:291-6.
62. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching LM. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 1999; 59:633-8. (Pubitemid 29076061)
63. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999; 59:1626-34. (Pubitemid 29160136)
64. Sun JR, Brown JM. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. Cancer Research 1989; 49:5664-70. (Pubitemid 19256449)
65. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 1994; 29:373-7. (Pubitemid 24166549)
66. Theys J, Landuyt W, Nuyts S, Van Mellaert L, Bosmans E, Rijnders A, et al. Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol Med Microbiol 2001; 30:37-41. (Pubitemid 32145002)
67. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001; 98:15155-60. (Pubitemid 34013985)
68. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60:7075-83. (Pubitemid 32059187)
69. Durand RE, Olive PL. Physiological and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Investig 1997; 5:213-9. (Pubitemid 27479449)